Overview

Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)

Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (standard proton pump inhibitor [PPI] treatment), in subjects with gastro-esophageal reflux (GERD) who have inadequate relief with PPIs.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Esomeprazole
Proton Pump Inhibitors